Details

Autor(en) / Beteiligte

• Dussupt, Vincent
• Sankhala, Rajeshwer S
• Gromowski, Gregory D
• Donofrio, Gina
• De La Barrera, Rafael A
• Larocca, Rafael A
• Zaky, Weam
• Mendez-Rivera, Letzibeth
• Choe, Misook
• Davidson, Edgar
• McCracken, Michael K
• Brien, James D
• Abbink, Peter
• Bai, Hongjun
• Bryan, Aubrey L
• Bias, Candace Hope
• Berry, Irina Maljkovic
• Botero, Nubia
• Cook, Tanya
• Doria-Rose, Nicole A
• Escuer, Ariadna Grinyo I
• Frimpong, Justice Akuoku
• Geretz, Aviva
• Hernandez, Mayda
• Hollidge, Bradley S
• Jian, Ningbo
• Kabra, Kareem
• Leggat, David J
• Liu, Jinyan
• Pinto, Amelia K
• Rutvisuttinunt, Wiriya
• Setliff, Ian
• Tran, Ursula
• Townsley, Samantha
• Doranz, Benjamin J
• Rolland, Morgane
• McDermott, Adrian B
• Georgiev, Ivelin S
• Thomas, Rasmi
• Robb, Merlin L
• Eckels, Kenneth H
• Barranco, Elizabeth
• Koren, Michael
• Smith, Darci R
• Jarman, Richard G
• George, Sarah L
• Stephenson, Kathryn E
• Barouch, Dan H
• Modjarrad, Kayvon
• Michael, Nelson L
• Joyce, M Gordon
• Krebs, Shelly J

Titel

Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor

Ist Teil von

• Nature medicine, 2020-02, Vol.26 (2), p.228-235

Ort / Verlag

United States: Nature Publishing Group

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Zika virus (ZIKV) has caused significant disease, with widespread cases of neurological pathology and congenital neurologic defects. Rapid vaccine development has led to a number of candidates capable of eliciting potent ZIKV-neutralizing antibodies (reviewed in refs. ). Despite advances in vaccine development, it remains unclear how ZIKV vaccination affects immune responses in humans with prior flavivirus immunity. Here we show that a single-dose immunization of ZIKV purified inactivated vaccine (ZPIV) in a dengue virus (DENV)-experienced human elicited potent cross-neutralizing antibodies to both ZIKV and DENV. Using a unique ZIKV virion-based sorting strategy, we isolated and characterized multiple antibodies, including one termed MZ4, which targets a novel site of vulnerability centered on the Envelope (E) domain I/III linker region and protects mice from viremia and viral dissemination following ZIKV or DENV-2 challenge. These data demonstrate that Zika vaccination in a DENV-experienced individual can boost pre-existing flavivirus immunity and elicit protective responses against both ZIKV and DENV. ZPIV vaccination in Puerto Rican individuals with prior flavivirus experience yielded similar cross-neutralizing potency after a single vaccination, highlighting the potential benefit of ZIKV vaccination in flavivirus-endemic areas.